Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 ; volume:13 ; number:1 ; day:26 ; month:6 ; year:2014 ; pages:1-13 ; date:12.2014
Molecular cancer ; 13, Heft 1 (26.6.2014), 1-13, 12.2014
- Urheber
-
Doloff, Joshua C.
Chen, Chong-Sheng
Waxman, David J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-13-158
- URN
-
urn:nbn:de:101:1-2021081501382857288022
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Doloff, Joshua C.
- Chen, Chong-Sheng
- Waxman, David J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Anti tumor activity of salvia officinalis is due to its anti-angiogenic, anti-migratory and anti-proliferative effects
Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway
Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L
The role of hypoxic signaling in evasive tumor resistance against anti-angiogenic therapy
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Anti tumor activity of salvia officinalis is due to its anti-angiogenic, anti-migratory and anti-proliferative effects
Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway
Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L
The role of hypoxic signaling in evasive tumor resistance against anti-angiogenic therapy
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited
Anti tumor activity of salvia officinalis is due to its anti-angiogenic, anti-migratory and anti-proliferative effects
Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway
Cytotoxicity, anti-angiogenic, anti-tumor and molecular docking studies on phytochemicals isolated from Polygonum hydropiper L
The role of hypoxic signaling in evasive tumor resistance against anti-angiogenic therapy
Anti-angiogenic alternatives to VEGF blockade
Anti-angiogenic therapies in brain metastases
Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial